无框架机器人辅助立体定向活检用于脑干病变:103例连续活检系列
该研究回顾性分析2001至2017年单中心96例患者(103次活检)接受无框架机器人辅助立体定向脑干病变活检的经验。最常见病变位于脑桥(62.1%),经小脑路径占61次(59.2%)。总体活检诊断率95.8%,永久性残疾3例(2.9%),短暂并发症17例(17.7%)。
要点
- 脑干病变无框架机器人辅助立体定向活检总体诊断率95.8%。
- 永久性残疾发生率2.9%(3例,均为成人),短暂并发症17.7%(17例)。
- 初次活检非结论性诊断10例(9.7%),二次活检后降至4例(4.1%)。
核心结论
- 无框架机器人辅助立体定向活检可为脑干病变的安全精准管理提供初始平台,诊断率高且永久性并发症发生率低。
研究设计与样本
- 回顾性分析2001至2017年单中心大学医院所有接受无框架机器人引导立体定向活检的患者,使用NeuroMate®机器人(Renishaw™,英国)。
- 共96例患者(103次活检),活检时平均年龄34.0岁(范围1-78岁)。
主要发现
- 最常见病变部位为脑桥(62.1%),经小脑路径61次(59.2%)。
- 最常见诊断为弥漫性胶质瘤(67.0%)、转移瘤(7.8%)和淋巴瘤(6.8%)。
- 非结论性诊断10例(9.7%),二次活检后降至4例(4.1%);总体活检诊断率95.8%。
- 永久性残疾3例(2.9%,均为成人),短暂并发症17例(17.7%);瘤内出血4例(其中1例迅速恶化并致命)。
- 72.9%的患者接受了辅助靶向治疗;神经外科平均随访2.2年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Targeted treatment for brainstem lesions requires above all a precise histopathological and molecular diagnosis. In the current technological era, robot-assisted stereotactic biopsies represent an accurate and safe procedure for tissue diagnosis. We present our center's experience in frameless robot-assisted biopsies for brainstem lesions. METHODS: We performed a retrospective analysis of all patients benefitting from a frameless robot-guided stereotactic biopsy at our University Hospital, from 2001 to 2017. Patients consented to the use of data and/or images. The NeuroMate® robot (Renishaw™, UK) was used. We report on lesion location, trajectory strategy, histopathological diagnosis and procedure safety. RESULTS: Our series encompasses 96 patients (103 biopsies) treated during a 17 years period. Mean age at biopsy: 34.0 years (range 1-78). Most common location: pons (62.1%). Transcerebellar approach: 61 procedures (59.2%). Most common diagnoses: diffuse glioma (67.0%), metastases (7.8%) and lymphoma (6.8%). Non conclusive diagnosis: 10 cases (9.7%). After second biopsy this decreased to 4 cases (4.1%). Overall biopsy diagnostic yield: 95.8%. Permanent disability was recorded in 3 patients (2.9%, all adults), while transient complications in 17 patients (17.7%). Four cases of intra-tumoral hematoma were recorded (one case with rapid decline and fatal issue). Adjuvant targeted treatment was performed in 72.9% of patients. Mean follow-up (in the Neurosurgery Department): 2.2 years. CONCLUSION: Frameless robot-assisted stereotactic biopsies can provide the initial platform towards a safe and accurate management for brainstem lesions, offering a high diagnostic yield with low permanent morbidity.
引用
- Peciu-Florianu I, Legrand V, Monfilliette-Djelad A, et al. Frameless robot-assisted stereotactic biopsies for lesions of the brainstem-a series of 103 consecutive biopsies. J Neurooncol. 2022. PMID: 35083580. doi:10.1007/s11060-022-03952-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。